Children and young adults scanned multiple times by computed tomography (CT) have a small increased risk of leukaemia and brain tumours in the decade following their first scan.
The findings from a study of more than 175,000 children and young adults was led by researchers at Newcastle University and at the National Cancer Institute, part of the National Institutes of Health, USA.
The researchers emphasise that when a child suffers a major head injury or develops a life-threatening illness, the benefits of clinically appropriate CT scans should outweigh future cancer risks.
Lead author Dr Mark Pearce, Reader in Lifecourse Epidemiology at Newcastle University said: ‘CT scans are accurate and fast so they should be used when their immediate benefits outweigh the long-term risks. However, now we have shown that CT scans increase the risk of cancer, we must ensure that when they are used they are fully justified from a clinical perspective.’
The study represents the culmination of almost two decades of research in this area at Newcastle University, and is jointly funded by the UK Department of Health and NCI/NIH.
CT imaging is a vital and commonly used diagnostic technique and it is used more frequently in countries such as the USA and Japan. However, CT scans deliver a dose of ionising radiation to the body part being scanned and to nearby tissues. Even at relatively low doses, ionising radiation can break the chemical bonds in DNA, causing damage to genes that may increase a person

As scientists continue making breakthroughs in personalised cancer treatment, delivering those therapies in the most cost-effective manner has become increasingly important. Now researchers at the University of Colorado School of Medicine have identified new ways of doing just that, allowing more patients to benefit from this revolution in cancer care.

In a paper health economist Adam Atherly, PhD, of the Colorado School of Public Health (CSPH) and medical oncologist D. Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, argue the cost of profiling patients

More than 30% of the one million heart attack victims in the United States each year die before seeking medical attention. Although widespread education campaigns describe the warning signs of a heart attack, the average time from the onset of symptoms to arrival at the hospital has remained at 3 hours for more than 10 years. In their upcoming article,’This is your heart speaking. Call 911,

Surgeons in Oxford are the first in the UK to successfully implant an electronic retina into the back of an eye.
On 22 March 2012, Chris James became the first patient in the UK to receive this ground-breaking surgery as part of a clinical trial being carried out at John Radcliffe Hospital and King’s College Hospital in London.
Mr James’s operation took place at the Oxford Eye Hospital with the surgical team led by Professor Robert MacLaren.
He was assisted by Mr Tim Jackson, a consultant ophthalmic surgeon at King’s College Hospital in London.
The following week, a second patient, Robin Millar, a 60 year old music producer from London, received a retinal implant at King’s College Hospital, with Professor MacLaren assisting Mr Jackson.
Both patients were able to detect light immediately after the electronic retinas were switched on, and are now beginning to experience some restoration of useful vision. Further operations are now planned for other suitable patients.
The retinal implants have been developed by Retina Implant of Germany to restore some sight to people with retinitis pigmentosa, an inherited condition that affects around one in every 3,000 – 4,000 people in Europe.
Retinitis pigmentosa is a progressive disease that sees light-detecting cells in the retina deteriorate over time.
Retina Implant’s devices are designed to replace the lost cells in the retina. Patients have a small microchip containing 1,500 tiny electronic light detectors implanted below the retina. The optic nerve is able to pick up electronic signals from the microchip and patients can begin to regain some sight once more.
Professor MacLaren explains: ‘What makes this unique is that all functions of the retina are integrated into the chip. It has 1,500 light sensing diodes and small electrodes that stimulate the overlying nerves to create a pixellated image. Apart from a hearing aid-like device behind the ear, you would not know a patient had one implanted.’
Chris James, 54, a council worker from Wiltshire, first began to experience night blindness in his mid-20s and was diagnosed with retinitis pigmentosa following a referral to Oxford Eye Hospital.
For a number of years, Chris’ vision remained relatively stable. But in 1990, a large dip in his vision left him legally blind. In 2003, another decrease in vision rendered Chris completely blind in his left eye and only able to distinguish lights in his right.
After having the artificial retina implanted in his left eye, Chris can now recognise a plate on a table and other basic shapes. And his vision is continuing to improve as he learns to use the electronic chip in an eye that has been completely blind for over a decade.
The operation took eight hours and first required implantation of the power supply which is buried under the skin behind the ear, similar to a cochlear implant. This part of the operation was performed by Mr James Ramsden of Oxford University Hospitals assisted by Mr Markus Groppe, an academic clinical lecturer at the University of Oxford.
The electronic retina was then inserted into the back of the eye and stitched into position before being connected to the power supply.
Three weeks after the operation, Chris’ electronic retina was switched on for the first time. After some initial tuning and testing, Chris was able to distinguish light against a black background.
‘As soon as I had this flash in my eye, this confirmed that my optic nerves are functioning properly which is a really promising sign,’ Chris said. ‘It was like someone taking a photo with a flashbulb, a pulsating light, I recognised it instantly.’
Chris continues to have monthly follow-up testing of his microchip. In the meantime, he is testing the microchip at home. ‘It’s obviously early days but it’s encouraging that I am already able to detect light where previously this would have not been possible for me. I’m still getting used to the feedback the chip provides and it will take some time to make sense of this. Most of all, I’m really excited to be part of this research.’
Oxford Eye Hospital